PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
42.53
+0.06 (+0.14%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close42.47
Open42.86
Bid42.40 x 21500
Ask42.53 x 800
Day's Range42.26 - 42.88
52 Week Range33.20 - 46.47
Volume35,818,356
Avg. Volume25,343,587
Market Cap245.843B
Beta (3Y Monthly)0.73
PE Ratio (TTM)10.74
EPS (TTM)3.96
Earnings DateJan 29, 2019
Forward Dividend & Yield1.44 (3.39%)
Ex-Dividend Date2019-01-31
1y Target Est45.35
Trade prices are not sourced from all markets
  • The Dogs of the Dow 2019: 10 Dividend Stocks to Watch
    Kiplinger8 hours ago

    The Dogs of the Dow 2019: 10 Dividend Stocks to Watch

    The "Dogs of the Dow" is a simple but successful value investing strategy that many on Wall Street swear by. It's easy: At the beginning of the year, buy the 10 highest-yielding dividend stocks in the Dow Jones Industrial Average. Hold them for a year. Next year, rinse and repeat. While this does result in higher-than-average income, the investment case really is a value one. The idea: A high dividend yield - in the kind of rock-solid blue-chip stocks the Dow tends to hold - implies that shares are oversold. Meanwhile, the continued payment of dividends shows that management remains confident in the company's earnings. Investors thus should profit both from an above-average yield, as well as an eventual recovery in share prices once Wall Street realizes its selling has gone too far. How well does the strategy work? In 2018, the Dogs of the Dow lost just 1.5% on average versus a 5.6% decline for the Dow and a 6.2% drop for the Standard & Poor's 500-stock index. The win marked the Dogs' fourth consecutive year of outperformance. And already in 2019, some Dogs are baring their fangs. Here are the 10 dividend stocks that make up the Dogs of the Dow, listed in order of their dividend yields as of the start of 2019. We also list their current yields, which have shifted a bit in the first few days of this year's trading. ### SEE ALSO: The 25 Best S&P; 500 Stocks of the Past 50 Years

  • 3 Stocks That Are Easy to Understand
    Motley Fool13 hours ago

    3 Stocks That Are Easy to Understand

    Keep it simple, shareholders, with these three stocks.

  • The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
    Zacks15 hours ago

    The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips

    The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips

  • GSK Chairman Hampton to step down ahead of split
    Reuters20 hours ago

    GSK Chairman Hampton to step down ahead of split

    The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer (PFE.N) would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.

  • Financial Times22 hours ago

    [$$] GSK chairman to step down ahead of break-up

    The search for Sir Philip’s successor will take up to nine months, according to someone familiar with the process, who said he would have completed about five years on the board when he eventually stepped down. On Monday shareholders said his successor should be someone adept in change management, perhaps having already overseen a merger or demerger, since the strategic “heavy lifting” had taken place on Sir Philip’s watch and a different set of skills was now required. One top-10 shareholder suggested it was crucial to ensure that the pharma business developed into “a self-funding entity” within the three-year timeframe set for the break-up.

  • Would Pfizer Shareholders Win With an Acquisition of Amarin?
    Motley Fool2 days ago

    Would Pfizer Shareholders Win With an Acquisition of Amarin?

    A Pfizer buyout of Amarin is still just a rumor. But rumors sometimes turn into reality.

  • Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
    Motley Fool2 days ago

    Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?

    The answer: It's complicated.

  • Top Stock Reports for Pfizer, Biogen & Schwab
    Zacks3 days ago

    Top Stock Reports for Pfizer, Biogen & Schwab

    Top Stock Reports for Pfizer, Biogen & Schwab

  • Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
    Zacks4 days ago

    Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

    Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

  • Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress
    Zacks4 days ago

    Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress

    The index enjoyed another strong week of gains, increasing over three straight sessions.

  • Baxter (BAX) Gains From Sharesource's Global Success Rates
    Zacks4 days ago

    Baxter (BAX) Gains From Sharesource's Global Success Rates

    Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.

  • GuruFocus.com4 days ago

    The Stable Value Stock Is Built to Weather Market Storms

    It is hard to say anything about McKesson (MCK) that we have not said before -- it is a high-quality business with extremely cheap shares. McKesson stock is not just cheap -- it's incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.

  • J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
    Zacks5 days ago

    J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect

    J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.

  • 3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group
    InvestorPlace5 days ago

    3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group

    Wednesday was another winner for Wall Street, but just barely. The S&P 500 ended the day up 0.22%, having peeled back from a high of 2,625.786 to close at 2,616.10. The weight of the rally since late December is starting to weigh on investors. Financial stocks, led by bank stocks, carried most of the gain's weight. Bank of America (NYSE:BAC) was up 7.2% after swinging to a record-breaking fourth quarter profit. Yet, had it not been for sweeping bullishness from the financial sector, the overall market may not have ended the day with any gain at all. Ford Motor Company (NYSE:F) fell more than 6% on a disappointing fourth quarter. Snap (NYSE:SNAP) fared even worse, however, losing 13.7% after losing CFO Tim Stone … the second CFO resignation in less than a year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Those disparate results are a microcosm of the environment right now, where the rising tide isn't lifting all boats equally. Going forward, traders will have to be more discriminate, and focus on stock charts like those of Fiserv (NASDAQ:FISV), Pfizer (NYSE:PFE) and PNC Financial Services Group (NYSE:PNC), which are better positioned to make trade-worthy moves. ### Fiserv (FISV) As odd as it may sound to cast a bullish light on Fiserv after it fell more than 4% at one point on Wednesday in response to news that it aims to acquire rival First Data (NYSE:FDC), in most regards the stumble was the capitulation the stock's needed for a while. * 10 Growth Stocks With the Future Written All Over Them Indeed, several clues already suggest that's exactly what happened yesterday. Click to Enlarge • The shape of yesterday's bar is telling in and of itself. After a poor open and then a sharp move to lower lows, the buyers came roaring back later in the day to force a close near the top of the range. The pivot has already been made. • Underscoring the potential capitulation is a huge volume surge. This indicates the last of the would-be sellers were finally flushed out. Now the buyers can start to trickle in without facing a headwind. • Curiously, yesterday's low around $68.50 was also last month's low, and last May's low. The bulls have drawn a line in the sand there. • Still, this is a scenario that requires a little follow-through to erase any lingering doubts that the reversal effort is for real. ### Pfizer (PFE) In yesterday's examination of the market's top three stock charts, the brewing bearishness of Merck (NYSE:MRK) was highlighted, but only because rivals like were also bumping into a headwind. When an entire group of stocks starts to struggle, it generally indicates a secular undertow that won't be easy to stop. In the meantime, Pfizer itself worked its way into a little more technical trouble, losing ground after being unable to press above its key moving averages too … moving averages that have formed bearish crosses while most other stocks are seeing bullish ones. Click to Enlarge • A couple of weeks ago the blue 20-day moving average line fell below the purple 50-day and gray 100-day moving average lines, and the 50-day line is close to breaking below the 100-day line. It all points to accelerating bearishness. • The selling volume has also been greater than the buying volume of late, even if both have been choppy. • The white 200-day moving average line at $40.27 has the potential to act as support should the potential selloff take shape, but there's an interim floor around $42.00 that would have to fail first before any of this weakness matters. ### PNC Financial Services Group (PNC) Finally, though almost all financial stocks were up on Wednesday, too many of them are now too overextended to bother stepping into now. Not PNC Financial Services Group, however. PNC is still closer to its recent low than not, with a whole lot of room to keep climbing. And, the recent chart action says this stock has built a near-perfect launch pad from which PNC will continue to rally. Click to Enlarge • Notice that PNC Financial Services shares have mostly stagnated since late last year, but within the past few days has started to log higher highs and higher closes. • Better yet, Wednesday's pullback to the blue 20-day moving average line was a perfect opportunity for the profit-takers to pile in. They didn't though, overwhelmed by the buyers waiting in the wings. Rising volume confirms more buyers are crawling out of the woodwork. • Zooming out to the weekly chart we can see the December pullback dragged PNC all the way to an established support line that extends back to March's lows. Each brush of that floor has resulted in a decent rebound. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group appeared first on InvestorPlace.

  • Associated Press5 days ago

    Court rules against Pfizer in religious discrimination suit

    TRENTON, N.J. (AP) — A woman who said she was fired by a major pharmaceutical company because of her religious beliefs won a court victory Wednesday when a state appeals panel ruled that she didn't agree in an online form to waive her rights to sue.

  • Why Ligand Pharmaceuticals Tanked 25%
    Market Realist5 days ago

    Why Ligand Pharmaceuticals Tanked 25%

    Why Ligand Pharmaceuticals Tanked 25%Ligand PharmaceuticalsToday, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day. At the same time, other pharmaceutical companies Amarin

  • Is Pfizer a Buy?
    Motley Fool6 days ago

    Is Pfizer a Buy?

    America's largest pharmaceutical company is about to show investors something they haven't seen in a while.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Pfizer Inc.

    # Pfizer Inc ### NYSE:PFE View full report here! ## Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.64 billion over the last one-month into ETFs that hold PFE are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Neutral The current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Pfizer (PFE) Gains But Lags Market: What You Should Know
    Zacks6 days ago

    Pfizer (PFE) Gains But Lags Market: What You Should Know

    Pfizer (PFE) closed at $42.73 in the latest trading session, marking a +0.85% move from the prior day.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks7 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • Why Amarin Is Soaring in First Half of January
    Market Realist7 days ago

    Why Amarin Is Soaring in First Half of January

    Why Amarin Is Soaring in First Half of JanuaryStock price hikeOn January 11, Amarin (AMRN) closed at $18.00, which is 1.91% lower than its previous closing price. However, on January 10, 2019, the company closed at $18.35, almost 22% higher than its

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zacks7 days ago

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • Here's How Pfizer Gained 20.5% in 2018
    Motley Fool7 days ago

    Here's How Pfizer Gained 20.5% in 2018

    While its industry was getting crushed, this big pharma surged forward.

  • Bulls bet on this biopharma company. Plus, the update on ...
    CNBC Videos3 days ago

    Bulls bet on this biopharma company. Plus, the update on ...

    "Halftime Report" traders Jon and Pete Najarian spot unusual options activity in shares of Macy's and Pfizer.

  • Fiserv to buy First Data in $22B all-stock deal
    CNBC Videos6 days ago

    Fiserv to buy First Data in $22B all-stock deal

    Fiserv announced plans to buy First Data in an all-stock transaction the companies valued at $22 billion.